Right on schedule, Alexza Pharmaceuticals won a late-afternoon US approval on 21 December to market its inhaled antipsychotic Adasuve (loxapine) to treat agitation associated with schizophrenia or bipolar I disorder in adults, although the drug came with and a black-box warning and must be dispensed through a restricted distribution program, which likely was the trigger for the sell-off of the firm's shares.
Alexza's Adasuve crosses US finish line, but distribution limited
Right on schedule, Alexza Pharmaceuticals won a late-afternoon US approval on 21 December to market its inhaled antipsychotic Adasuve (loxapine) to treat agitation associated with schizophrenia or bipolar I disorder in adults, although the drug came with and a black-box warning and must be dispensed through a restricted distribution program, which likely was the trigger for the sell-off of the firm's shares.
More from Neurological
More from Therapeutic Category
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.